Weekly Digest – July 2024 Weekly Digest – July 2024 01 July 2024: Eisai Announces independent development and commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) Eisai and Bristol Myers Squibb are ending their $650 million collaboration on the […]
Contact:
info@ciscientists.com
+1-908-212-7484
Optimal Dose
For a subscription, please provide your email id